bluebird bio
BLUE

$1.22

0.83%

Market Cap: 235M

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 4 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

55% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 40

17% less funds holding

Funds holding: 186 [Q4 2023] → 155 (-31) [Q1 2024]

26% less capital invested

Capital invested by funds: $180M [Q4 2023] → $134M (-$46.4M) [Q1 2024]

41% less call options, than puts

Call options by funds: $1.48M | Put options by funds: $2.49M

56% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 55

65.8% less ownership

Funds ownership: 119.18% [Q4 2023] → 53.38% (-65.8%) [Q1 2024]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$1.02

16%

downside

Avg. target

$3.42

181%

upside

High target

$8

556%

upside

4 analyst ratings

0 positive

0%

3 neutral

75%

1 negative

25%

RBC Capital Luca Issi	556%upside $8	Sector Perform Reiterated	27 Mar 2024
Wells Fargo Yanan Zhu	146%upside $3	Equal-Weight Maintained	27 Mar 2024
Wedbush David Nierengarten	38%upside $1.68	Neutral Maintained	19 Mar 2024
HSBC Morten Herholdt	16%downside $1.02	Reduce Maintained	5 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about BLUE published over the past 30 days

BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bluebird bio Inc. (NASDAQ: BLUE) on behalf of long-term stockholders following a class action complaint that was filed against Blue on March 28, 2024 with a Class Period from April 24, 2023 to December 8, 2023. Our investigation concerns whether the board of directors of Blue have breached their fiduciary duties to the company.

BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to its chief financial officer, James Sterling, with a grant date of July 1, 2024. The stock options approved under the Inducement Plan have an exercise price per share equal to $0.98, the fair market value of the Company's common stock on the g.

bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)

BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bluebird bio Inc. (NASDAQ: BLUE) on behalf of long-term stockholders following a class action complaint that was filed against Blue on March 28, 2024 with a Class Period from April 24, 2023 to December 8, 2023. Our investigation concerns whether the board of directors of Blue have breached their fiduciary duties to the company.

BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline

Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

CHICAGO , June 2, 2024 /PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner Dr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in the biopharmaceutical industry leading clinical development of multiple medicines across various therapeutic areas.

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

Bluebird bio appoints new CFO to oversee financial restatements

Gene therapy maker bluebird bio on Wednesday named former Renalytix finance chief James Sterling as its CFO to oversee the revision of the company's financial statements.

Bluebird bio appoints new CFO to oversee financial restatements

bluebird bio Appoints O. James Sterling as Chief Financial Officer

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease. “We are thrilled to welcome James to bluebird bio. We are confident that his extensive experience in the healthcare sector and knowledge of the capital markets wil.

bluebird bio Appoints O. James Sterling as Chief Financial Officer

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming May 28, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On December 8, 2023, bluebird announced that it had receive.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit - BLUE

NEW YORK , May 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of bluebird bio investors who were adversely affected by alleged securities fraud between April 24, 2023 and December 8, 2023.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit - BLUE

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE

NEW YORK , May 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE

See News Rankings